FGF21-engineered ADSCs promote diabetic wound healing by mitigating ferroptosis and oxidative stress via the SIRT1/NRF2/GPX4 signaling pathway

Our study establishes ADSC^FGF21 as a multimodal therapy for diabetic wounds, synergizing stem cell-mediated tissue repair with FGF21's metabolic regulation. By activating the SIRT1/NRF2/GPX4 axis, ADSC^FGF21 restores redox homeostasis and blocks ferroptosis. These findings provide a promising strategy for chronic wound management.